Clinical Trial Update: Multi-site Decision Impact Study for Decipher

View source ↗

Summary

A multi-site decision impact study involving the Decipher genomic classifier by GenomeDx Biosciences for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: GenomeDx Biosciences Corp | Conditions: Prostate Cancer | Status: COMPLETED